# Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

> **NCT01087294** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 85 (actual)

## Conditions studied

- Leukemia, B-cell
- Lymphoma, Hodgkins
- Lymphoma, Non-hodgkins
- Lymphoma, B-Cell

## Interventions

- **PROCEDURE:** Allogeneic stem cell transplant
- **BIOLOGICAL:** Anti-CD19-chimeric-antigen-receptor-transduced T cells
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT01087294
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-04
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-04-02
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01087294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01087294, "Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01087294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*